Paper36588676
Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae.
Yu Z and 18 others. Front Pharmacol, 2022. Cited by 28 papers, by iCite.
Cite this record
ConductScience Library. Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae. Papers, record 36588676. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36588676
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References61
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29238962 | Population Pharmacokinetics of Polymyxin B. | Clin Pharmacol Ther | 2018 | https://conductscience.org/library/papers/29238962 | PubMed |
| 2 | 17890940 | Pharmacokinetic-pharmacodynamic crisis in the elderly. | Am J Ther | 2007 | https://conductscience.org/library/papers/17890940 | PubMed |
| 3 | 27998750 | Clinical translation of polymyxin-based combination therapy: Facts, challenges and future opportunities. | J Infect | 2017 | https://conductscience.org/library/papers/27998750 | PubMed |
| 4 | 23776390 | Acute respiratory muscle weakness and apnea in a critically ill patient induced by colistin neurotoxicity: key potential role of hemoadsorption elimination during continuous venovenous hemofiltration. | Int J Nephrol Renovasc Dis | 2013 | https://conductscience.org/library/papers/23776390 | PubMed |
| 5 | 20573659 | fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. | J Antimicrob Chemother | 2010 | https://conductscience.org/library/papers/20573659 | PubMed |
| 6 | 18922815 | In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. | J Antimicrob Chemother | 2008 | https://conductscience.org/library/papers/18922815 | PubMed |
| 7 | 20585118 | Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. | Antimicrob Agents Chemother | 2010 | https://conductscience.org/library/papers/20585118 | PubMed |
| 8 | 30950096 | Population pharmacokinetics of immediate- and prolonged-release tacrolimus formulations in liver, kidney and heart transplant recipients. | Br J Clin Pharmacol | 2019 | https://conductscience.org/library/papers/30950096 | PubMed |
| 9 | 30722960 | Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection. | Int J Antimicrob Agents | 2019 | https://conductscience.org/library/papers/30722960 | PubMed |
| 10 | 20961911 | Polymyxin B versus other antimicrobials for the treatment of pseudomonas aeruginosa bacteraemia. | J Antimicrob Chemother | 2011 | https://conductscience.org/library/papers/20961911 | PubMed |
| 11 | 32052041 | Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing Position Statements on Polymyxin B and Colistin Clinical Breakpoints. | Clin Infect Dis | 2020 | https://conductscience.org/library/papers/32052041 | PubMed |
| 12 | 33782834 | Population Pharmacokinetics of Vixotrigine in Healthy Volunteers and Subjects with Trigeminal Neuralgia, Painful Lumbosacral Radiculopathy and Erythromelalgia. | Eur J Drug Metab Pharmacokinet | 2021 | https://conductscience.org/library/papers/33782834 | PubMed |
| 13 | 25604744 | Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. | J Antimicrob Chemother | 2015 | https://conductscience.org/library/papers/25604744 | PubMed |
| 14 | 30423057 | Phenotypic and Genotypic Characterization of Carbapenem-resistant Enterobacteriaceae: Data From a Longitudinal Large-scale CRE Study in China (2012-2016). | Clin Infect Dis | 2018 | https://conductscience.org/library/papers/30423057 | PubMed |
| 15 | 17878146 | Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. | J Antimicrob Chemother | 2007 | https://conductscience.org/library/papers/17878146 | PubMed |
| 16 | 28893690 | New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? | Clin Microbiol Infect | 2017 | https://conductscience.org/library/papers/28893690 | PubMed |
| 17 | 23124906 | Comparison of polymyxin B with other antimicrobials in the treatment of ventilator-associated pneumonia and tracheobronchitis caused by Pseudomonas aeruginosa or Acinetobacter baumannii. | Infection | 2013 | https://conductscience.org/library/papers/23124906 | PubMed |
| 18 | 24566187 | In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. | Antimicrob Agents Chemother | 2014 | https://conductscience.org/library/papers/24566187 | PubMed |
| 19 | 32184115 | Pharmacokinetic/pharmacodynamic adequacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in critically ill, general ward and cystic fibrosis patient populations. | Int J Antimicrob Agents | 2020 | https://conductscience.org/library/papers/32184115 | PubMed |
| 20 | 29800496 | Polymyxin B Pharmacokinetics in Adult Cystic Fibrosis Patients. | Pharmacotherapy | 2018 | https://conductscience.org/library/papers/29800496 | PubMed |
Cited by23
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42712890 | A population pharmacokinetic model library for polymyxin B: clinical implementation of model-informed precision dosing. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42712890 | PubMed |
| 42582048 | Association of polymyxin B MIC with pharmacokinetic/pharmacodynamic target attainment and clinical outcomes in carbapenem-resistant enterobacterales infections. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42582048 | PubMed |
| 42489755 | Factors Affecting Pharmacokinetics and Dosing Strategies of Polymyxin B in Multidrug-resistant Gram-negative Infected Patients with Renal Impairment: A Systematic Review with Expert Opinion. | Eur J Drug Metab Pharmacokinet | 2026 | https://conductscience.org/library/papers/42489755 | PubMed |
| 42422069 | Can the two-point method based on peak and trough concentrations accurately estimate the area under the curve of polymyxin B? A Monte Carlo simulation study. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42422069 | PubMed |
| 42321962 | Polymyxin B Intravenous Administration Strategy Guided by Minimum Inhibitory Concentration in Critically Ill Patients With Pulmonary Infection: Insights From PBPK Modeling. | CPT Pharmacometrics Syst Pharmacol | 2026 | https://conductscience.org/library/papers/42321962 | PubMed |
| 42243196 | Clinician decision-making for polymyxin dosing in critically ill patients with renal impairment: a qualitative study. | Sci Rep | 2026 | https://conductscience.org/library/papers/42243196 | PubMed |
| 41490412 | Safety and therapeutic potential evaluation of Cefotaxime plus Polymyxin B against polymyxin-carbapenem resistant Klebsiella pneumoniae in a murine model. | PLoS One | 2026 | https://conductscience.org/library/papers/41490412 | PubMed |
| 40906716 | Determining minimal inhibitory concentrations and antibiotic susceptibility for Enterobacterales by flow cytometry using reactive oxygen species as a marker. | PLoS One | 2025 | https://conductscience.org/library/papers/40906716 | PubMed |
| 40284021 | Biomarker-Driven Pharmacokinetics and Efficacy of Polymyxin B in Critically Ill Patients with XDR-GN Pneumonia. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40284021 | PubMed |
| 40246790 | A Systematic Review of Pharmacokinetic Studies of Colistin and Polymyxin B in Adult Populations. | Clin Pharmacokinet | 2025 | https://conductscience.org/library/papers/40246790 | PubMed |
| 40170884 | Aerosolized delivery resulting in high polymyxin B concentration levels in epithelial lining fluid ensures efficacy in ventilator-associated pneumonia. | JAC Antimicrob Resist | 2025 | https://conductscience.org/library/papers/40170884 | PubMed |
| 40078873 | Monte Carlo simulation to optimize polymyxin B dosing regimens for the treatment of Gram-negative bacteremia. | Front Cell Infect Microbiol | 2025 | https://conductscience.org/library/papers/40078873 | PubMed |
| 40047414 | Clinical outcomes and pharmacokinetics/pharmacodynamics of intravenous polymyxin B treatment for various site carbapenem-resistant gram-negative bacterial infections: a prospective observational multicenter study. | Antimicrob Agents Chemother | 2025 | https://conductscience.org/library/papers/40047414 | PubMed |
| 39984645 | Flash optimization of drug combinations for Acinetobacter baumannii with IDentif.AI-AMR. | NPJ Antimicrob Resist | 2025 | https://conductscience.org/library/papers/39984645 | PubMed |
| 39254296 | Synergistic antimicrobial combination of third-generation cephalosporins and polymyxin B against carbapenem-polymyxin-resistant Klebsiella pneumoniae: an in vitro and in vivo analysis. | Antimicrob Agents Chemother | 2024 | https://conductscience.org/library/papers/39254296 | PubMed |
| 39050834 | Efficacy and Safety Factors Related to Plasma Concentration-Optimized Polymyxin B Therapy in Treating Carbapenem-Resistant Gram-Negative Bacterial Infections in China. | Infect Drug Resist | 2024 | https://conductscience.org/library/papers/39050834 | PubMed |
| 38974043 | Polymyxins: recent advances and challenges. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/38974043 | PubMed |
| 38847855 | How can polymyxin B be dosed based on current pharmacokinetic knowledge? | Eur J Clin Pharmacol | 2024 | https://conductscience.org/library/papers/38847855 | PubMed |
| 38483544 | Pharmacokinetics of polymyxin B in different populations: a systematic review. | Eur J Clin Pharmacol | 2024 | https://conductscience.org/library/papers/38483544 | PubMed |
| 38212555 | Clinical Efficacy and Safety of Colistin Sulfate in the Treatment of Carbapenem-Resistant Organism Infections in Patients with Hematological Diseases. | Infect Dis Ther | 2024 | https://conductscience.org/library/papers/38212555 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| GPT | 2875 | PubTator's text mining | https://conductscience.org/library/genes/2875 | NCBI Gene |
| SLC17A5 | 26503 | PubTator's text mining | https://conductscience.org/library/genes/26503 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36588676
GET https://conductscience.org/api/papers/v1/36588676/references?page=2